Company Overview of Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; CONTEMPO that is in the Phase Ib/II study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; BRAVURA, which is in Phase III study to evaluate the safety and efficacy of IPI-145 plu...
784 Memorial Drive
Cambridge, MA 02139
Key Executives for Infinity Pharmaceuticals, Inc.
Chairman, Chief Executive Officer and President
Total Annual Compensation: $646.9K
Chief Financial Officer, Principal Accounting Officer, Chief Business Officer and Executive Vice President
Total Annual Compensation: $405.4K
President of Research & Development
Total Annual Compensation: $497.3K
Chief Commercial Officer and Executive Vice President
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2015.
Infinity Pharmaceuticals, Inc. Key Developments
Infinity Pharmaceuticals, Inc. Announces Executive Changes
Jul 26 16
On July 25, 2016, Christopher M. Lindblom, Infinity Pharmaceuticals, Inc.’s Vice President of Finance and Treasurer, agreed to transition his role as its principal accounting officer to Lawrence E. Bloch, M.D., J.D., its Executive Vice President, Chief Financial Officer and Chief Business Officer, effective July 25, 2016. Mr. Lindblom will continue in his role as Vice President of Finance and Treasurer. On July 25, 2016, Lawrence E. Bloch, M.D., J.D. was appointed to serve as principal accounting officer, effective immediately. Dr. Bloch, has served as Executive Vice President, Chief Financial Officer and Chief Business Officer since July 2012. Prior to joining the company, Dr. Bloch served as Chief Executive Officer of NeurAxon, Inc., from 2007 to 2011.
Infinity Pharmaceuticals, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-13-2016 10:15 AM
Jul 7 16
Infinity Pharmaceuticals, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-13-2016 10:15 AM. Venue: Le Parker Meridien, New York, New York, United States.
Infinity Pharma Lays Off Another 100 After AbbVie Ends Partnership
Jun 28 16
Infinity Pharmaceuticals is laying off another 100 employees just two weeks after laying off 46 researchers, this time after AbbVie opted out of a partnership on its main drug. The 100 new layoffs cut headcount by 58%, but added to the cuts announced June 14 when disappointing trial results of its blood cancer drug duvelisib was first announced.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|